Cost Analysis of a Novel Enzymatic Debriding Agent for Management of Burn Wounds

Abstract EN

Introduction.

Given its efficacy and safety, NexoBrid™ (NXB) has become part of our therapeutic options in burns treatment with satisfactory results.

However, no cost analysis comparing NXB to the standard of care (SOC) has been carried out as of today.

Aim.

To assess the cost of treatment with NXB and compare it to the SOC cost.

Methods.

20 patients with 14–22% of TBSA with an intermediate-deep thermal burn related injury were retrospectively and consecutively included.

10 of these patients were treated with the SOC, while the other 10 with NXB.

The cost analysis was performed in accordance with the weighted average Italian Health Ministry DRGs and with Conferenza Stato/Regioni 2003 and the study by Tan et al.

For each cost, 95% confidence intervals have been evaluated.

Results.

Considering the 10 patients treated with NXB, the overall savings (total net saving) amounted to 53300 euros.

The confidence interval analysis confirmed the savings.

Discussion.

As shown by our preliminary results, significant savings are obtained with the use of NXB.

The limit of our study is that it is based on Italian health care costs and assesses a relative small cohort of patients.

Further studies on larger multinational cohorts are warranted.